NEWARK, U.S.A. and NANJING, China — CTTQ Pharma, partner of Biosion today announced that the Phase II trial of BSI-045B/TQC2731 for the treatment of Chronic Rhinosinusitis with Nasal Polyps is now active and recruiting patients.
BSI-045B/TQC2731 is a high-affinity, humanized monoclonal antibody, targeting thymic stromal lymphopoietin (TSLP), a cytokine that is implicated in the pathogenesis of atopic dermatitis, asthma and other eosinophilic and Th2 immune-related diseases. Biosion’s collaboration partner - CTTQ, a China-based pharmaceutical company with rights to BSI-045B (TQC2731) for China development and commercialization, is currently conducting a Phase II clinical trial of BSI-045B in China for the treatment of severe uncontrolled asthma and CRSwNP.
Click on the link to view more information
About Biosion, Inc.
BIOSION ALL RIGHTS RESERVED.
NEWARK, U.S.A. and NANJING, China — CTTQ Pharma, partner of Biosion today announced that the Phase II trial of BSI-045B/TQC2731 for the treatment of Chronic Rhinosinusitis with Nasal Polyps is now active and recruiting patients.
BSI-045B/TQC2731 is a high-affinity, humanized monoclonal antibody, targeting thymic stromal lymphopoietin (TSLP), a cytokine that is implicated in the pathogenesis of atopic dermatitis, asthma and other eosinophilic and Th2 immune-related diseases. Biosion’s collaboration partner - CTTQ, a China-based pharmaceutical company with rights to BSI-045B (TQC2731) for China development and commercialization, is currently conducting a Phase II clinical trial of BSI-045B in China for the treatment of severe uncontrolled asthma and CRSwNP.
Click on the link to view more information
About Biosion, Inc.
BIOSION ALL RIGHTS RESERVED.